^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Debio 0123

    i
    Other names: Debio 0123, Debio-0123, Debio0123
    Associations

    News

    Trials
    Company:
    Almac Discovery, Debiopharm
    Drug class:
    WEE1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    2ms
    WIN-B: Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer (clinicaltrials.gov)
    P1/2, N=76, Not yet recruiting, MedSIR
    New P1/2 trial • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Trodelvy (sacituzumab govitecan-hziy) • Debio 0123
    6ms
    Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy (clinicaltrials.gov)
    P1, N=78, Recruiting, Debiopharm International SA | N=54 --> 78
    Enrollment change
    |
    carboplatin • etoposide IV • Debio 0123
    7ms
    Debio 0123-101: Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=115, Recruiting, Debiopharm International SA | Trial completion date: Jun 2025 --> Apr 2027
    Trial completion date • Combination therapy • Metastases
    |
    carboplatin • Debio 0123
    7ms
    MYTHIC: Study of RP-6306 Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=364, Recruiting, Repare Therapeutics | N=180 --> 364
    Enrollment change • Combination therapy • Metastases
    |
    lunresertib (RP-6306) • Debio 0123 • camonsertib (RP-3500)
    9ms
    A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=155, Recruiting, Debiopharm International SA | Trial primary completion date: Jun 2025 --> Jan 2026
    Trial primary completion date • Metastases
    |
    Debio 0123
    9ms
    A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma (clinicaltrials.gov)
    P1/2, N=120, Recruiting, Debiopharm International SA | N=89 --> 120 | Trial completion date: Mar 2028 --> Sep 2028 | Trial primary completion date: Jan 2025 --> Sep 2028
    Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
    |
    IDH wild-type
    |
    temozolomide • Debio 0123
    11ms
    Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy (clinicaltrials.gov)
    P1, N=54, Recruiting, Debiopharm International SA
    Trial completion date • Trial primary completion date • Combination therapy
    |
    carboplatin • etoposide IV • Debio 0123
    1year
    A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=130, Recruiting, Debiopharm International SA | Trial completion date: Dec 2023 --> Jun 2027 | Trial primary completion date: Aug 2023 --> Jun 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    Debio 0123
    over2years
    The WEE1 inhibitor Debio 0123 enhances the efficacy of standard of care DNA damaging agents in lung cancer models (AACR 2022)
    Taken together these results highlight that inhibiting WEE1 with Debio 0123 significantly improves tumor response to SOC DNA damaging agents in models of SCLC, providing the foundation for future clinical exploration of Debio 0123 in SCLC.
    Clinical • Preclinical • Tumor Mutational Burden
    |
    TMB (Tumor Mutational Burden)
    |
    TMB-H
    |
    carboplatin • etoposide IV • Debio 0123